CareMax (CMAX) Misses Q2 EPS by 21c; Offers FY23 Revenue Guidance

CareMax (NASDAQ: CMAX) reported Q2 EPS of ($0.29), $0.21 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $224.4 million versus the consensus estimate of $184.41 million.

GUIDANCE:

CareMax sees FY2023 revenue of $750-800 million, versus the consensus of $740 million.

For earnings history and earnings-related data on CareMax (CMAX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance